{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:31:03Z","timestamp":1782995463237,"version":"3.54.5"},"reference-count":21,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Bisphosphonates are effective for hypercalcemia of malignancy (HOM). Efficacy and safety data for bisphosphonates in parathyroid hormone\u2013related hypercalcemia (PTHRH) are rare, including pamidronate (Pam), which is not indicated for this condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This work aims to evaluate the efficacy and safety of Pam for moderate-to-severe PTHRH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective case-control study was conducted at a tertiary care medical center. Patients included adults hospitalized with serum calcium levels greater than 12 mg\/dL, from October 29, 2013 to December 17, 2019. Etiology was categorized as PTHRH or PTH-independent. Clinical and laboratory data of PTHRH patients treated with Pam (PTHRH-Pam+) were compared to Pam-untreated counterparts (PTHRH-Pam\u2013).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-four patients with 37 hospitalizations for PTHRH (Pam-treated and -untreated) met the inclusion criteria. Pam was given in 24 of 37 cases (64.8%). Admission serum calcium levels for the PTHRH-Pam+ group were higher than for PTHRH-Pam\u2013 group (14.4 mg\/dL vs 13.0 mg\/dL, P\u2005=\u2005.005). Median total Pam dose was 60 mg (range, 30-180 mg) in the treated group. Serum calcium decreased 3.5 mg\/dL for PTHRH-Pam+ vs 1.6 mg\/dL for PTHRH-Pam\u2013 (P\u2005=\u2005.003). No PTHRH-Pam+ patients developed hypocalcemia or acute kidney injury. Nadir serum phosphorus levels were lower in the PTHRH-Pam+ vs PTHRH-Pam\u2013 group (1.7 mg\/dL vs 2.4 mg\/dL, respectively, P\u2005=\u2005.004). Three PTHRH-Pam+ patients developed severe hypophosphatemia; all resolved with intravenous and oral supplementation. Seventeen patients underwent parathyroidectomy, of whom 10 received Pam within 28 days preoperatively. Postoperatively, 4 developed hypocalcemia and 3 hypophosphatemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study demonstrates that Pam is effective and safe for treating PTHRH, while ensuring close laboratory monitoring of calcium and phosphorus metabolism. Larger, prospective studies are needed to establish the role of Pam and other potent bisphosphonates in moderate-to-severe PTHRH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab457","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T16:49:20Z","timestamp":1624380560000},"page":"e4593-e4602","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3920-2238","authenticated-orcid":false,"given":"Rachel Chava","family":"Rosenblum","sequence":"first","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Twito","sequence":"additional","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Barzilay-Yoseph","sequence":"additional","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erez","family":"Ramaty","sequence":"additional","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Klein","sequence":"additional","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pnina","family":"Rotman-Pikielny","sequence":"additional","affiliation":[{"name":"Endocrine Institute, Meir Medical Center, Kfar Saba 44281, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"issue":"3","key":"2021120108542557000_CIT0001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","article-title":"Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages","volume":"95","author":"Nussbaum","year":"1993","journal-title":"Am J Med."},{"issue":"2","key":"2021120108542557000_CIT0002","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol."},{"key":"2021120108542557000_CIT0003","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag."},{"issue":"800","key":"2021120108542557000_CIT0004","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/pgmj.68.800.434","article-title":"Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia","volume":"68","author":"Dodwell","year":"1992","journal-title":"Postgrad Med J."},{"issue":"4","key":"2021120108542557000_CIT0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med."},{"issue":"3","key":"2021120108542557000_CIT0006","first-page":"321","article-title":"Acute hyperparathyroidism: our experience with 36 cases","volume":"75","author":"Gasparri","year":"2004","journal-title":"Ann Ital Chir."},{"issue":"2","key":"2021120108542557000_CIT0007","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jss.2011.04.010","article-title":"Hypercalcemic crisis in the era of targeted parathyroidectomy","volume":"171","author":"Beck","year":"2011","journal-title":"J Surg Res."},{"issue":"1","key":"2021120108542557000_CIT0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13613-019-0606-8","article-title":"Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients","volume":"9","author":"Mousseaux","year":"2019","journal-title":"Ann Intensive Care."},{"issue":"3","key":"2021120108542557000_CIT0009","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"Ahmad","year":"2015","journal-title":"Am J Med."},{"issue":"1","key":"2021120108542557000_CIT0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone."},{"issue":"2","key":"2021120108542557000_CIT0011","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","article-title":"Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Chow","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021120108542557000_CIT0012","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021120108542557000_CIT0013","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2265.1990.tb00869.x","article-title":"Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status","volume":"32","author":"Schmidli","year":"1990","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2021120108542557000_CIT0014","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00007611-199606000-00020","article-title":"Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism","volume":"89","author":"Tal","year":"1996","journal-title":"South Med J."},{"issue":"3","key":"2021120108542557000_CIT0015","first-page":"132","article-title":"Primary hyperparathyroidism. An alternative to the surgery [article in Spanish]","volume":"56","author":"Diaz Guardiola","year":"2009","journal-title":"Endocrinol Nutr"},{"issue":"3","key":"2021120108542557000_CIT0016","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","article-title":"Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2021120108542557000_CIT0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00774-005-0680-x","article-title":"Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism","volume":"24","author":"Lee","year":"2006","journal-title":"J Bone Miner Metab."},{"issue":"1","key":"2021120108542557000_CIT0018","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/2230-8210.196023","article-title":"Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism","volume":"21","author":"Mayilvaganan","year":"2017","journal-title":"Indian J Endocrinol Metab."},{"issue":"10","key":"2021120108542557000_CIT0019","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2021120108542557000_CIT0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fendo.2017.00079","article-title":"Contemporary medical management of primary hyperparathyroidism: a systematic review","volume":"8","author":"Leere","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"2021120108542557000_CIT0021","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"QJM."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab457\/39073190\/dgab457.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/11\/e4593\/41378533\/dgab457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/11\/e4593\/41378533\/dgab457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:43:46Z","timestamp":1638366226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/11\/e4593\/6307869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":21,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6,22]]},"published-print":{"date-parts":[[2021,10,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab457","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,6,22]]}}}